GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (MEX:NVS N) » Definitions » Cyclically Adjusted PS Ratio

Novartis AG (MEX:NVS N) Cyclically Adjusted PS Ratio : 4.34 (As of Jul. 05, 2025)


View and export this data going back to 2008. Start your Free Trial

What is Novartis AG Cyclically Adjusted PS Ratio?

As of today (2025-07-05), Novartis AG's current share price is MXN2092.19. Novartis AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was MXN481.54. Novartis AG's Cyclically Adjusted PS Ratio for today is 4.34.

The historical rank and industry rank for Novartis AG's Cyclically Adjusted PS Ratio or its related term are showing as below:

MEX:NVS N' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.83   Med: 3.8   Max: 4.87
Current: 4.66

During the past years, Novartis AG's highest Cyclically Adjusted PS Ratio was 4.87. The lowest was 2.83. And the median was 3.80.

MEX:NVS N's Cyclically Adjusted PS Ratio is ranked worse than
76.66% of 737 companies
in the Drug Manufacturers industry
Industry Median: 2.15 vs MEX:NVS N: 4.66

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Novartis AG's adjusted revenue per share data for the three months ended in Mar. 2025 was MXN140.799. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is MXN481.54 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Novartis AG Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Novartis AG's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Cyclically Adjusted PS Ratio Chart

Novartis AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.98 3.84 3.88 4.11 4.25

Novartis AG Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.19 4.58 4.65 4.25 4.64

Competitive Comparison of Novartis AG's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Novartis AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novartis AG's Cyclically Adjusted PS Ratio falls into.


;
;

Novartis AG Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Novartis AG's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=2092.19/481.54
=4.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Novartis AG's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=140.799/107.7224*107.7224
=140.799

Current CPI (Mar. 2025) = 107.7224.

Novartis AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 82.554 100.464 88.519
201509 86.535 99.785 93.418
201512 90.977 99.386 98.608
201603 84.778 99.475 91.807
201606 97.659 100.088 105.108
201609 99.383 99.604 107.483
201612 108.562 99.380 117.676
201703 92.884 100.040 100.017
201706 95.171 100.285 102.229
201709 97.641 100.254 104.915
201712 53.557 100.213 57.570
201803 86.410 100.836 92.312
201806 97.603 101.435 103.653
201809 91.093 101.246 96.920
201812 99.785 100.906 106.526
201903 95.000 101.571 100.754
201906 99.000 102.044 104.509
201909 107.279 101.396 113.973
201912 103.955 101.063 110.805
202003 130.007 101.048 138.595
202006 116.432 100.743 124.498
202009 120.320 100.585 128.858
202012 113.482 100.241 121.952
202103 114.560 100.800 122.428
202106 117.197 101.352 124.563
202109 121.940 101.533 129.374
202112 41.982 101.776 44.435
202203 114.054 103.205 119.046
202206 119.061 104.783 122.401
202209 99.495 104.835 102.236
202212 99.070 104.666 101.963
202303 93.926 106.245 95.232
202306 96.112 106.576 97.146
202309 101.508 106.570 102.606
202312 96.378 106.461 97.520
202403 97.834 107.355 98.169
202406 115.257 107.991 114.970
202409 127.953 107.468 128.256
202412 140.818 107.128 141.599
202503 140.799 107.722 140.799

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novartis AG  (MEX:NVS N) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Novartis AG Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Novartis AG's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Novartis AG Business Description

Address
Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Novartis AG Headlines

No Headlines